[Corrections] Correction to Lancet Oncol 2022; 23: 888–98

Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 2022; 23: 888–98—In this Article, the second sentence of the paragraph on treatment-related serious adverse events in the Results section should read “The most common any-grade treatment-related serious adverse events were diarrhoea (11 [3%]), pneumonitis (nine [3%]), and adrenal insufficiency (six [2%]) in the nivolumab plus cabozantinib group, and anaemia (four [1%]), hyponatraemia (three [<1%]), and thrombocytopenia (three [<1%]) in the sunitinib group (appendix p 19).” This correction has been made to the online version as of June 27, 2022, and the printed version is correct.